{"Lymphocyte-activation": [0], "gene": [1], "3": [2, 192], "(LAG-3)": [3], "and": [4, 26, 37, 51, 71, 207, 222, 248], "programmed": [5], "death": [6], "1": [7], "(PD-1)": [8], "are": [9], "distinct": [10], "inhibitory": [11], "immune": [12, 219], "checkpoints": [13], "that": [14], "contribute": [15], "to": [16, 34, 38, 88, 122, 134, 148, 167, 178, 230], "T-cell": [17], "exhaustion.": [18], "The": [19, 97], "combination": [20, 76, 251], "of": [21, 201, 210, 217, 235], "relatlimab,": [22], "a": [23, 28, 74, 225], "LAG-3-blocking": [24], "antibody,": [25, 30], "nivolumab,": [27], "PD-1-blocking": [29], "has": [31], "been": [32], "shown": [33], "be": [35], "safe": [36], "have": [39], "antitumor": [40], "activity": [41, 52], "in": [42, 53, 199, 203, 208, 212, 238, 250], "patients": [43, 54, 89, 202, 211, 239], "with": [44, 55, 79, 90, 124, 128, 136, 169, 173, 180, 228, 240], "previously": [45, 56, 91, 241], "treated": [46], "melanoma,": [47], "but": [48], "the": [49, 154, 204, 213], "safety": [50, 255], "untreated": [57, 92, 242], "melanoma": [58], "need": [59], "investigation.In": [60], "this": [61], "phase": [62], "2-3,": [63], "global,": [64], "double-blind,": [65], "randomized": [66], "trial,": [67], "we": [68], "evaluated": [69], "relatlimab": [70], "nivolumab": [72, 80, 137, 214, 249], "as": [73, 77, 104, 126, 171], "fixed-dose": [75], "compared": [78, 127, 172], "alone": [81, 237], "when": [82], "administered": [83], "intravenously": [84], "every": [85], "4": [86, 194], "weeks": [87], "metastatic": [93, 243], "or": [94, 142, 193, 244], "unresectable": [95, 245], "melanoma.": [96, 246], "primary": [98], "end": [99], "point": [100], "was": [101, 114, 162], "progression-free": [102, 112, 231], "survival": [103, 113, 158, 183, 232], "assessed": [105], "by": [106, 153, 258], "blinded": [107], "independent": [108], "central": [109], "review.The": [110], "median": [111], "10.1": [115], "months": [116, 130, 161], "(95%": [117, 131, 164, 175], "confidence": [118], "interval": [119], "[CI],": [120], "6.4": [121], "15.7)": [123], "relatlimab-nivolumab": [125, 170, 188, 205], "4.6": [129], "CI,": [132, 146, 165, 176], "3.4": [133], "5.6)": [135], "(hazard": [138], "ratio": [139], "for": [140], "progression": [141], "death,": [143], "0.75": [144], "[95%": [145], "0.62": [147], "0.92];": [149], "P": [150], "=": [151], "0.006": [152], "log-rank": [155], "test).": [156], "Progression-free": [157, 182], "at": [159], "12": [160], "47.7%": [163], "41.8": [166], "53.2)": [168], "36.0%": [174], "30.5": [177], "41.6)": [179], "nivolumab.": [181, 190], "across": [184], "key": [185], "subgroups": [186], "favored": [187], "over": [189], "Grade": [191], "treatment-related": [195], "adverse": [196], "events": [197], "occurred": [198], "18.9%": [200], "group": [206], "9.7%": [209], "group.The": [215], "inhibition": [216, 234], "two": [218], "checkpoints,": [220], "LAG-3": [221], "PD-1,": [223], "provided": [224], "greater": [226], "benefit": [227], "regard": [229], "than": [233], "PD-1": [236], "Relatlimab": [247], "showed": [252], "no": [253], "new": [254], "signals.": [256], "(Funded": [257], "Bristol": [259], "Myers": [260], "Squibb;": [261], "RELATIVITY-047": [262], "ClinicalTrials.gov": [263], "number,": [264], "NCT03470922.).": [265]}